Integrated Filing — IndAS

General information about company
Scrip Code	500680
NSE Symbol	PFIZER
MSEI Symbol	NA
ISIN	INE182A01018
Name of company	PFIZER LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	19-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	13-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Half Yearly
Reporting Quarter	Yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	19-May-2025   12:15:00
End date and time of board meeting	19-May-2025   19:30:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-01-31
Indicate Company website link for updated RPT policy of the Company	www.pfizerltd.co.in
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
Not Applicable

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Oct-2024	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	5919100000	22813500000
	Other income	445800000	1722500000
	Total income	6364900000	24536000000
2	Expenses
(a)	Cost of materials consumed	706400000	2723400000
(b)	Purchases of stock-in-trade	1395200000	5127500000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-76800000	253600000
(d)	Employee benefit expense	829100000	3713300000
(e)	Finance costs	26900000	84100000
(f)	Depreciation, depletion and amortisation expense	164000000	607900000
(f)	Other Expenses
1	Other Expenses	790200000	3593400000
	Total other expenses	790200000	3593400000
	Total expenses	3835000000	16103200000
3	Total profit before exceptional items and tax	2529900000	8432800000
4	Exceptional items	1728100000	1728100000
5	Total profit before tax	4258000000	10160900000
6	Tax expense
7	Current tax	990600000	2641000000
8	Deferred tax	-42000000	-156100000
9	Total tax expenses	948600000	2484900000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	3309400000	7676000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	3309400000	7676000000
17	Other comprehensive income net of taxes	23500000	7400000
18	Total Comprehensive Income for the period	3332900000	7683400000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	457500000	457500000
	Face value of equity share capital	10	10
27	Details of debt securities
22	Reserves excluding revaluation reserve		0
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	72.34	167.79
	Diluted earnings (loss) per share from continuing operations	72.34	167.79
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	72.34	167.79
	Diluted earnings (loss) per share from continuing and discontinued operations	72.34	167.79
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		1. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of nDirectors at their meeting held on May 19, 2025. n n2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards nInd AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and nin terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015 as amended from time to time. n n3. The financial results for the year ended March 31, 2025 have been audited by the statutory auditors of the nCompany. The audit opinion does not contain any modifications. The audit report will be filed with the Stock nExchanges and will also be available on the Company's website - www.pfizerltd.co.in n n4. Figures for the quarter ended March 31, 2025 and March 31, 2024 represent the difference between the naudited figures in respect of the full financial year and published unaudited figures of nine months ended nDecember 31, 2024 and December 31, 2023 respectively which were subject to a limited review by the nstatutory auditors. n n5. Exceptional item n nIn the previous year the Company had entered into an agreement to assign and assume the Lease nof MIDC Land and Sale of Building constructed on such land for transferring and assigning Pfizer nunexpired leasehold rights in the land situated at Thane and sale of structures and buildings nconstructed thereon, to Zoetis Pharmaceutical Research Private Limited, for a lumpsum nconsideration of Rs. 264.40 crore, of which Rs. 52.88 crore had been received as an advance. The said nassets were classified as held for sale. During the quarter ended 31 March 2025 the Company has nreceived requisite approvals from MIDC and has completed the transfer and sale of said assets. Net ngain of Rs. 172.81 crore net of carrying value of Rs. 31.75 crore and cost to sell Premium and other ncharges Rs. 59.84 crore net of recovery is disclosed as an Exceptional items in the financial results. n nFor the year ended March 31, 2024, the exceptional item is in relation to provision for old pending nVAT CST litigations. The Company opted for Maharashtra VAT Amnesty Scheme for certain years nand had received final settlement orders. Pursuant to the said orders, the Company had written back nan excess provision of Rs. 7 .95 crore. n n6. The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments nis not applicable and accordingly not made. n n7. The Board of Directors have recommended a final dividend of Rs. 35 per equity share of Rs. 10 each 350% and a special dividend of Rs. 100 per equity share of Rs. 10 each 1000 in view of 75th year of Pfizer in India and a special dividend of Rs. 30 per equity share of Rs. 10 each 300 in view of the gain on transfer of assignment of leasehold land and building constructed on such land thereon, totaling to a dividend of Rs.165 per equity share of Rs. 10 each for the financial year ended March 31, 2025. These proposed dividends amounting to Rs. 754.84 crore are subject to the approval ofthe shareholders in the annual general meeting. n n8.The Company does not have any subsidiary company or associate company or joint venture company as at nMarch 31, 2025.

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	1718200000
	Capital work-in-progress	76400000
	Investment property	0
	Goodwill	5274900000
	Other intangible assets	243100000
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	0
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	139300000
	Total non-current financial assets	139300000
	Deferred tax assets (net)	693000000
	Other non-current assets	5837700000
	Total non-current assets	13982600000
2	Current assets
	Inventories	4759200000
	Current financial asset
	Current investments	0
	Trade receivables, current	1930900000
	Cash and cash equivalents	4950700000
	Bank balance other than cash and cash equivalents	23059100000
	Loans, current	0
	Other current financial assets	39000000
	Total current financial assets	29979700000
	Current tax assets (net)	0
	Other current assets	389600000
	Total current assets	35128500000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	49111100000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	457500000
	Other equity	41716600000
	Total equity attributable to owners of parent	42174100000
	Non controlling interest
	Total equity	42174100000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	676200000
	Total non-current financial liabilities	676200000
	Provisions, non-current	565700000
	Deferred tax liabilities (net)	0
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	1241900000
	Current liabilities
	Current financial liabilities
	Borrowings, current	25000000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	112700000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1403300000
	Total Trade payable	1516000000
	Other current financial liabilities	783500000
	Total current financial liabilities	2324500000
	Other current liabilities	647600000
	Provisions, current	513400000
	Current tax liabilities (Net)	2209600000
	Deferred government grants, Current	0
	Total current liabilities	5695100000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	6937000000
	Total equity and liabilites	49111100000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Oct-2024	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Oct-2024	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
	Total Amount of items that will not be reclassified to profit and loss
2	Income tax relating to items that will not be reclassified to profit or loss	-31400000	-9900000
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	7900000	2500000
5	Total Other comprehensive income	23500000	7400000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			10160900000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			84100000
	Adjustments for decrease (increase) in inventories			-422200000
	Adjustments for decrease (increase) in trade receivables, current			-68200000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			0
	Adjustments for decrease (increase) in other non-current assets			676100000
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			-153100000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			219400000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			607900000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			315900000
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			2100000
	Adjustments for dividend income			0
	Adjustments for interest income			0
	Adjustments for share-based payments			136600000
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-1728100000
	Other adjustments to reconcile profit (loss)			-99000000
	Other adjustments for non-cash items			0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-428500000
	Net cash flows from (used in) operations			9732400000
	Dividends received			0
	Interest paid			0
	Interest received			-1572700000
	Income taxes paid (refund)			1562200000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			6597500000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			2000000
	Purchase of property, plant and equipment			281500000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			1516800000
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			1393600000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-3344300000
	Net cash flows from (used in) investing activities	-713400000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			0
	Payments of lease liabilities			447900000
	Dividends paid			1602500000
	Interest paid			3000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-2053400000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			3830700000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			3830700000
	Cash and cash equivalents cash flow statement at beginning of period			1120000000
	Cash and cash equivalents cash flow statement at end of period			4950700000